The future of medicine rests on data: the evidence that is the basis for the discovery, development and dispensing of prescription products and all other healthcare decisions. Data, and the analysis of that data, informs drug development, portfolio decisions, prescribing behaviors, patient compliance and reimbursement policy in value-based healthcare systems. Mastering the collection and interpretation of data is therefore vital for the vitality and continued global contributions of the biopharmaceutical industry.

This report will explore how connecting disparate streams of data can create a portfolio of evidence—valuable insights that can make the difference in today’s biopharmaceutical marketplace. While these opportunities for connections exist across all disease and therapeutic areas, they may be most acutely needed in the complex and dynamic area of oncology.